Our study was the first to determine whether pre-treatment tumor expressions of survivin, p53, cyclin D1, OPN and FN might help to predict the response to naCHT in pediatric inoperable and/or metastatic MPNST. This evidence concerns the gene TP53 and malignant peripheral nerve sheath tumor.